-
NMPA Announcement on the Revision of the Package Insert of Metoclopramide
2021-07-05
In accordance with the results of adverse drug reaction evaluation, to further protect drug safety for the people, the NMPA decided to modify the items of [Adverse reactions], [Contraindications] and [Precautions] in the package inserts of Metoclopramide.
-
NMPA Announcement on the Issues Related to the Implementation of the Measures for the Implementation of the Mechanism for Early Settlement of Drug Patent Disputes (interim)
2021-07-04
In order to complete the implementation of the Measures for the Implementation of the Mechanism for Early Settlement of Drug Patent Disputes (interim) (hereinafter referred to as the Measures), relevant issues are hereby announced on July 4 as follows.
-
Announcement of National Medical Products Administration and National Intellectual Property Administration on the Issuance of the Measures for the Implementation of the Mechanism for Early Settlement of Drug Patent Disputes (Interim)
2021-07-04
The National Medical Products Administration and the China National Intellectual Property Administration formulated the Measures for the Implementation of the Mechanism for Early Settlement of Drug Patent Disputes (interim).
-
NMPA Announcement on Issuing the Catalogue of Reference Preparations of Generic Drugs (Forty-two Batch)
2021-06-25
On June 22, the Catalogue of Reference Preparations of Generic Drugs (Forty-two Batch) was issued, upon review and determination by the NMPA Experts Committee of Quality and Efficacy Consistency Evaluation of Generic Drugs.
-
NMPA Announcement on the Revision of the Package Insert of Somatostatin for Injection
2021-06-24
The NMPA decided to modify the items of [Adverse reactions],[Precautions] and [Drug Interactions] in the package inserts of somatostatin for injection.
-
NMPA Announcement on the Revision of the Package Insert of the Oxiracetam Preparations
2021-06-24
The NMPA decided to modify the items of [Adverse reactions], [Contraindications] and [Precautions] in the package inserts of oxiracetam preparations. On June 22, relevant issues are hereby announced as follows.
